InflaRx N.V. (NASDAQ:IFRX) Stock Has Average Target Price of $7.43

InflaRx N.V. (NASDAQ:IFRX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $7.43.

Several equities research analysts have recently commented on IFRX shares. Zacks Research downgraded shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Monday, September 21st. Cantor Fitzgerald increased their target price on shares of InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Needham & Company LLC began coverage on shares of InflaRx in a report on Monday, September 14th. They set a “buy” rating and a $8.00 price target for the company.

Get InflaRx alerts:

View Our Latest Research Report on InflaRx

Hedge Funds Weigh In On InflaRx

A number of institutional investors and hedge funds have recently bought and sold shares of IFRX. Montanova Capital LLC grew its stake in shares of InflaRx by 189.1% during the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock valued at $51,372,000 after purchasing an additional 15,000,000 shares during the last quarter. Spruce Street Capital LP acquired a new stake in shares of InflaRx in the second quarter valued at approximately $11,988,924. ADAR1 Capital Management LLC bought a new position in InflaRx in the 2nd quarter worth approximately $6,720,000. 683 Capital Management LLC raised its position in InflaRx by 47.3% in the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after purchasing an additional 1,065,000 shares during the last quarter. Finally, Eversept Partners LP raised its position in InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after purchasing an additional 26,677 shares during the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Trading Down 0.6%

Shares of NASDAQ:IFRX opened at $1.59 on Tuesday. The firm has a market capitalization of $234.32 million, a PE ratio of -2.74 and a beta of 2.59. InflaRx has a 1-year low of $0.80 and a 1-year high of $2.95. The business’s 50 day moving average is $1.99 and its 200-day moving average is $1.89.

InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, sell-side analysts predict that InflaRx will post -0.31 EPS for the current year.

InflaRx Company Profile

(Get Free Report)

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for severe and life-threatening inflammatory diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune system that can contribute to tissue damage when excessively activated.

InflaRx’s lead product is vilobelimab, a monoclonal antibody designed to selectively block the complement protein C5a while preserving other components of the immune response.

Recommended Stories

• Five stocks we like better than InflaRx
• The Pentagon’s $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
• Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
• Salesforce Just Got a Rare Double Upgrade—What Changed?
• OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.